This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: Inter-University Research Institute Corporation Research Organization of Information and Systems, Ludwig Institute for Cancer Research Limited. Active years: 1993-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 5 
2 out of 530 
Years Active: 1993-2026
Title: Fuyuki Ishikawa: Innovator in Endothelial Cell Growth Factor Research
Introduction
Fuyuki Ishikawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the study of endothelial cell growth factors. With a total of 4 patents to his name, Ishikawa's work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Ishikawa's latest patents focus on peptides derived from endothelial cell growth factor, specifically the platelet-derived endothelial cell growth factor (PD-ECGF). This 45 kDa endothelial cell mitogen has been purified to homogeneity from human platelets. Notably, PD-ECGF does not bind to heparin and does not stimulate the proliferation of fibroblasts, distinguishing it from other endothelial mitogens in the fibroblast growth factor (FGF) family. Recent data suggest that PD-ECGF possesses angiogenic activity in vitro, which refers to its ability to stimulate the formation of new blood vessels and exhibit chemotactic activity. The inventions provide a homogeneous PD-ECGF in significantly greater yields than previously available, along with the primary structure of PD-ECGF, antibodies against it, clones of its cDNA, and variants thereof. Additionally, the inventions include a therapeutic preparation of PD-ECGF.
Career Highlights
Fuyuki Ishikawa is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in endothelial cell growth factors. His work has garnered attention for its innovative approach to understanding and utilizing PD-ECGF in therapeutic contexts.
Collaborations
Ishikawa has collaborated with notable researchers in his field, including Kohei Miyazono and Fumimaro Takaku. These collaborations have contributed to the depth and breadth of his research endeavors.
Conclusion
Fuyuki Ishikawa's contributions to the field of endothelial cell growth factors, particularly through his patents on PD-ECGF, highlight his role as an innovator in biomedical research. His work has the potential to lead to significant advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile